de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development

MPG-Autoren
http://pubman.mpdl.mpg.de/cone/persons/resource/persons44106

Beggel,  Bastian
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;
International Max Planck Research School, MPI for Informatics, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Svicher, V., Cento, V., Salpini, R., Mercurio, F., Fraune, M., Beggel, B., et al. (2011). Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Digestive and Liver Disease, 43(12), 975-983. doi:10.1016/j.dld.2011.07.002.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0010-1372-0
Zusammenfassung
Background: Impact of hepatitis B virus genetic barrier, defined as the number and type of nucleotide substitutions required to overcome drug/immune selective pressure, on drug-resistance/immune-escape development is unknown. Methods: Genetic barrier was calculated according to Van de Vijver (2006) in 3482 hepatitis B virusreverse transcriptase/HBV surface antigen sequences from 555 drug-naïve patients and 2927 antiviraltreated patients infected with hepatitis B virus genotypes A-G. Results: Despite high natural variability, genetic barrier for drug-resistance development is identical amongst hepatitis B virus genotypes, but varies according to drug-resistance mutation type. Highest genetic barrier is found for secondary/compensatory mutations (e.g. rtL80I/V–rtL180M–rtV173L), whilst most primary mutations (including rtM204V–rtA181T/V–rtI169T–rtA194T) are associated with low genetic barrier. An exception is rtM204I, which can derive from a transition or a transversion. Genotypes A and G are more prone to develop immune/diagnostic-escape mutations sT114R and sG130N. Vaccine-escape associated sT131N-mutation is a natural polymorphism in both A and G genotypes. Conclusion: Genetic barrier and reverse transcriptase/HBV surface antigen overlapping can synergistically influence hepatitis B virus drug-resistance/immune-escape development. The different immune-escape potential of specific hepatitis B virus genotypes could have important clinical consequences in terms of disease progression, vaccine strategies and correct HBV surface antigen detection.